-
1
-
-
0001817958
-
Epidemiology of movement disorders
-
Marsden CD, Fahn S, editors. London: Butterworths
-
Schoenberg BS. Epidemiology of movement disorders. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworths, 1987: 17-32
-
(1987)
Movement Disorders
, vol.2
, pp. 17-32
-
-
Schoenberg, B.S.1
-
2
-
-
0027889327
-
Medication use by the elderly
-
Stockton P, Jones JK. Medication use by the elderly. Aging Clin Exp Res 1993; 5 (5): 337-47
-
(1993)
Aging Clin Exp Res
, vol.5
, Issue.5
, pp. 337-347
-
-
Stockton, P.1
Jones, J.K.2
-
3
-
-
0030798539
-
Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
-
Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211-4
-
(1997)
Drug Metab Dispos
, vol.25
, pp. 1211-1214
-
-
Wynalda, M.A.1
Wienkers, L.C.2
-
4
-
-
0029994771
-
Antiparkinsonian agents: Drug interactions of clinical significance
-
Pfeiffer RF. Antiparkinsonian agents: drug interactions of clinical significance. Drug Saf 1996; 14 (5): 343-54
-
(1996)
Drug Saf
, vol.14
, Issue.5
, pp. 343-354
-
-
Pfeiffer, R.F.1
-
7
-
-
0026668120
-
Anticholinergic effects of drugs commonly prescribed for the elderly: Potential means for assessing risk of delirium
-
Tune L, Carr S, Hong E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4
-
(1992)
Am J Psychiatry
, vol.149
, pp. 1393-1394
-
-
Tune, L.1
Carr, S.2
Hong, E.3
-
8
-
-
0017225588
-
Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man
-
Algeri S, Cerletti C, Curcio M, et al. Effect of anticholinergic drugs on gastrointestinal absorption of L-dopa in rats and in man. Eur J Pharmacol 1976; 35: 293-9
-
(1976)
Eur J Pharmacol
, vol.35
, pp. 293-299
-
-
Algeri, S.1
Cerletti, C.2
Curcio, M.3
-
9
-
-
0029928467
-
The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers
-
Roberts J, Waller DG, von Renwick AG, et al. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. Br J Clin Pharmacol 1996; 41: 331-7
-
(1996)
Br J Clin Pharmacol
, vol.41
, pp. 331-337
-
-
Roberts, J.1
Waller, D.G.2
Von Renwick, A.G.3
-
11
-
-
0021823653
-
Pharmacologic changes in dopaminergic systems induced by long term administration of amantadine
-
Gianutsos G, Chute S, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long term administration of amantadine. Eur J Pharmacol 1985; 110: 357-61
-
(1985)
Eur J Pharmacol
, vol.110
, pp. 357-361
-
-
Gianutsos, G.1
Chute, S.2
Dunn, J.P.3
-
12
-
-
0017181731
-
Anticholinergic and membrane activities of amantadine in neuromuscular transmission
-
Nastuck WC, Su PC, Doublet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264: 76-9
-
(1976)
Nature
, vol.264
, pp. 76-79
-
-
Nastuck, W.C.1
Su, P.C.2
Doublet, P.3
-
13
-
-
0026751312
-
Amantadine as N-methyl-D-aspartic acid receptor antagonist: New possibilities for therapeutic applications?
-
Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol 1992; 94 Suppl.: S4-6
-
(1992)
Clin Neurol
, vol.94
, Issue.SUPPL.
-
-
Stoof, J.C.1
Booij, J.2
Drukarch, B.3
-
14
-
-
0029688949
-
Amantadine-induced vocal myoclonus
-
Pfeiffer RF. Amantadine-induced vocal myoclonus [letter]. Mov Disord 1996; 11 (1): 104-51
-
(1996)
Mov Disord
, vol.11
, Issue.1
, pp. 104-151
-
-
Pfeiffer, R.F.1
-
15
-
-
0013832252
-
Absorption, distribution, and excretion of amantadine hydrochloride
-
Bleidner WE, Harman JB, Hewes WE, et al. Absorption, distribution, and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965; 150: 484-90
-
(1965)
J Pharmacol Exp Ther
, vol.150
, pp. 484-490
-
-
Bleidner, W.E.1
Harman, J.B.2
Hewes, W.E.3
-
16
-
-
0024846923
-
Case report: Toxic delirium in a patient taking amantadine and trimethopim-sulfamethoxazole
-
Speeg KV, Leighton JA, Maldonoado AL. Case report: toxic delirium in a patient taking amantadine and trimethopim-sulfamethoxazole. Am J Med Sci 1989; 298: 410-2
-
(1989)
Am J Med Sci
, vol.298
, pp. 410-412
-
-
Speeg, K.V.1
Leighton, J.A.2
Maldonoado, A.L.3
-
18
-
-
0026094867
-
Bromocriptine-associated headache: Possible life-threatening sympathomimetic reaction
-
Kulig K, Moore LL, Kirk M, et al. Bromocriptine-associated headache: possible life-threatening sympathomimetic reaction. Obst Gynecol 1991; 78: 941-3
-
(1991)
Obst Gynecol
, vol.78
, pp. 941-943
-
-
Kulig, K.1
Moore, L.L.2
Kirk, M.3
-
19
-
-
0025324182
-
Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine in normal subjects
-
Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine in normal subjects [abstract]. Clin Pharmacol Ther 1990; 47: 166
-
(1990)
Clin Pharmacol Ther
, vol.47
, pp. 166
-
-
Nelson, M.V.1
Berchou, R.C.2
Kareti, D.3
-
20
-
-
2442740655
-
Enhancement of bromocriptine clinical effect and plasma levels with erythromycin
-
Sibley WA, Laguna JF. Enhancement of bromocriptine clinical effect and plasma levels with erythromycin. Excerpta Med 1981; 548: 329-30
-
(1981)
Excerpta Med
, vol.548
, pp. 329-330
-
-
Sibley, W.A.1
Laguna, J.F.2
-
21
-
-
0018854781
-
Alcohol increases bromocriptine side effects
-
Ayres J, Maseley MN. Alcohol increases bromocriptine side effects [letter]. N Engl J Med 1980; 302: 806
-
(1980)
N Engl J Med
, vol.302
, pp. 806
-
-
Ayres, J.1
Maseley, M.N.2
-
22
-
-
0017596822
-
Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months
-
Schwinn G, Dirks H, McIntosh C, et al. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months. Eur J Clin Invest 1977; 7: 101-7
-
(1977)
Eur J Clin Invest
, vol.7
, pp. 101-107
-
-
Schwinn, G.1
Dirks, H.2
McIntosh, C.3
-
23
-
-
0017694704
-
Sodium nitroprusside and epidural blockade to treat severe ergotism
-
Andersen PK, Christensen KN, Hole P, et al. Sodium nitroprusside and epidural blockade to treat severe ergotism. N Engl J Med 1977; 296: 1271-3
-
(1977)
N Engl J Med
, vol.296
, pp. 1271-1273
-
-
Andersen, P.K.1
Christensen, K.N.2
Hole, P.3
-
24
-
-
0025317247
-
Pergolide: A review of its pharmacological properties and therapeutic potential in Parkinson's disease
-
Langtry HD, Clissold SP. Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs 1990; 39: 491-506
-
(1990)
Drugs
, vol.39
, pp. 491-506
-
-
Langtry, H.D.1
Clissold, S.P.2
-
25
-
-
0029958441
-
High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum
-
Piercey ME, Walker EL, Feldpausch DL, et al. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Let 1996; 219: 138-40
-
(1996)
Neurosci Let
, vol.219
, pp. 138-140
-
-
Piercey, M.E.1
Walker, E.L.2
Feldpausch, D.L.3
-
26
-
-
0030753601
-
Clinical evaluation of pramipexole in advanced Parkinson's disease
-
Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease. Neurology 1997; 49: 162-8
-
(1997)
Neurology
, vol.49
, pp. 162-168
-
-
Lieberman, A.1
Ranhosky, A.2
Korts, D.3
-
27
-
-
0343770946
-
-
Kalamazoo (MI): Pharmacia and Upjohn Co., Jun
-
Pharmacia and Upjohn Co. Mirapex package insert. Kalamazoo (MI): Pharmacia and Upjohn Co., Jun 1997
-
(1997)
Mirapex Package Insert
-
-
-
28
-
-
0343335098
-
-
Crawley. UK: SmithKline Beecham, Sep
-
SmithKline Beecham. Requip package insert. Crawley. UK: SmithKline Beecham, Sep 1997
-
(1997)
Requip Package Insert
-
-
-
29
-
-
0030804074
-
Ropinirole for the treatment of early Parkinson's disease
-
Adler CH, Sethi KD, Davis TL, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49: 393-9
-
(1997)
Neurology
, vol.49
, pp. 393-399
-
-
Ch, A.1
Sethi, K.D.2
Davis, T.L.3
-
30
-
-
0003979209
-
-
SmithKline Beecham
-
Data on file, SmithKline Beecham
-
Data on File
-
-
-
31
-
-
0001560527
-
A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease
-
Kreider MS, Knox S, Gardiner D, et al. A multicenter double blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease [abstract]. Neurology 1996; 46: A475
-
(1996)
Neurology
, vol.46
-
-
Kreider, M.S.1
Knox, S.2
Gardiner, D.3
-
33
-
-
0023265840
-
3-O-methyldopa and the response to levodopa in Parkinson's disease
-
Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987; 21: 584-8
-
(1987)
Ann Neurol
, vol.21
, pp. 584-588
-
-
Nutt, J.G.1
Woodward, W.R.2
Gancher, S.T.3
-
34
-
-
0026526135
-
Levodopa: Pharmacology, pharmacokinetics and pharmacodynamics
-
Juncos JJ. Levodopa: pharmacology, pharmacokinetics and pharmacodynamics. Neurol Clin North Am 1992; 10: 487-509
-
(1992)
Neurol Clin North Am
, vol.10
, pp. 487-509
-
-
Juncos, J.J.1
-
35
-
-
0015374287
-
The effect of an antacid administration on the absorption and metabolism of levodopa
-
Leon AS, Spiegel HE. The effect of an antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972; 12: 263-7
-
(1972)
J Clin Pharmacol New Drugs
, vol.12
, pp. 263-267
-
-
Leon, A.S.1
Spiegel, H.E.2
-
36
-
-
0023634716
-
Single dose pharmacokinetics of Madopar HBS in patients and the effect of food and antacid on the absorption of Madopar HBS in volunteers
-
Malcolm SL, Allen JG, Bird H, et al. Single dose pharmacokinetics of Madopar HBS in patients and the effect of food and antacid on the absorption of Madopar HBS in volunteers. Eur Neurol 1987; 27: 28-35
-
(1987)
Eur Neurol
, vol.27
, pp. 28-35
-
-
Malcolm, S.L.1
Allen, J.G.2
Bird, H.3
-
38
-
-
0024600260
-
Ferrous sulfate reduces levodopa bioavailability: Chelation as a possible mechanism
-
Campbell NRC, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther 1989; 45: 220-5
-
(1989)
Clin Pharmacol Ther
, vol.45
, pp. 220-225
-
-
Campbell, N.R.C.1
Hasinoff, B.2
-
39
-
-
0025149525
-
Sinemet-ferrous sulphate interaction in patients with Parkinson's disease
-
Campbell NRC, Rankine D, Goodridge AE, et al. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Br J Clin Pharmacol 1990; 30: 599-605
-
(1990)
Br J Clin Pharmacol
, vol.30
, pp. 599-605
-
-
Campbell, N.R.C.1
Rankine, D.2
Goodridge, A.E.3
-
40
-
-
0018819764
-
Interacticm of levodopa and metoclopramide on gastric emptying
-
Berkowitz DM, McCallum RW. Interacticm of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980; 27: 415-20
-
(1980)
Clin Pharmacol Ther
, vol.27
, pp. 415-420
-
-
Berkowitz, D.M.1
McCallum, R.W.2
-
41
-
-
0007367712
-
Parkinsonism occurring with methyldopa treatment
-
Groden BM. Parkinsonism occurring with methyldopa treatment [letter]. BMJ 1963; 2: 1001
-
(1963)
BMJ
, vol.2
, pp. 1001
-
-
Groden, B.M.1
-
42
-
-
7144221653
-
Parkinsonism associated with alpha-methyldopa therapy
-
Peastin MJT. Parkinsonism associated with alpha-methyldopa therapy [letter]. BMJ 1964; 2: 168
-
(1964)
BMJ
, vol.2
, pp. 168
-
-
Peastin, M.J.T.1
-
43
-
-
0014031392
-
Parkinsonism occurring during methyldopa therapy
-
Strang RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966; 95: 928-9
-
(1966)
Can Med Assoc J
, vol.95
, pp. 928-929
-
-
Strang, R.R.1
-
44
-
-
0019128272
-
Exacerbation of parkinsonism by methyldopa
-
Rosenblum AM, Montgomery EB. Exacerbation of parkinsonism by methyldopa. J Am Med 1980; 244: 2727-8
-
(1980)
J Am Med
, vol.244
, pp. 2727-2728
-
-
Rosenblum, A.M.1
Montgomery, E.B.2
-
45
-
-
0015922966
-
Interaction between levodopa and methyldopa
-
Gibberd FB, Small E. Interaction between levodopa and methyldopa. BMJ 1973; 2: 90-1
-
(1973)
BMJ
, vol.2
, pp. 90-91
-
-
Gibberd, F.B.1
Small, E.2
-
46
-
-
0017256736
-
Clonidine and the antiparkinsonian response to L-dopa or piribedil
-
Shoulson I, Chase TN. Clonidine and the antiparkinsonian response to L-dopa or piribedil. Neuropharmacolouy 1976; 15: 25-7
-
(1976)
Neuropharmacolouy
, vol.15
, pp. 25-27
-
-
Shoulson, I.1
Chase, T.N.2
-
47
-
-
0015736359
-
Interactions between levodopa and other drugs: Significance in the treatment of Parkinson's disease
-
Bianchine JR, Sunyapridakul L. Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease. Drugs 1973; 6: 364-88
-
(1973)
Drugs
, vol.6
, pp. 364-388
-
-
Bianchine, J.R.1
Sunyapridakul, L.2
-
49
-
-
0017863880
-
Deprenyl administration in man: A selective monoamine oxidase inhibitor without the 'cheese effect'
-
Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase inhibitor without the 'cheese effect'. Psychopharmacolopy 1978; 57: 33-8
-
(1978)
Psychopharmacolopy
, vol.57
, pp. 33-38
-
-
Elsworth, J.D.1
Glover, V.2
Reynolds, G.P.3
-
50
-
-
0019992365
-
Adverse interaction of levodopa with tricyclic antidepressanls
-
Edwards M. Adverse interaction of levodopa with tricyclic antidepressanls. Practitioner 1982; 226: 1448-9
-
(1982)
Practitioner
, vol.226
, pp. 1448-1449
-
-
Edwards, M.1
-
51
-
-
0016743254
-
Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man
-
Morgan JP, Riviera-Calimlim L, Messiha F, et al. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029-34
-
(1975)
Neurology
, vol.25
, pp. 1029-1034
-
-
Morgan, J.P.1
Riviera-Calimlim, L.2
Messiha, F.3
-
52
-
-
0026515520
-
Impaired levodopa response in Parkinson's disease during melanoma therapy
-
Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson's disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69-74
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 69-74
-
-
Merello, M.1
Esteguy, M.2
Perazzo, F.3
-
53
-
-
0026515520
-
Impaired levodopa response in Parkinson's Disease during melanoma therapy
-
Merello M, Esteguy M, Perazzo F, et al. Impaired levodopa response in Parkinson's Disease during melanoma therapy. Clin Neuropharmacol 1992; 15: 69-74
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 69-74
-
-
Merello, M.1
Esteguy, M.2
Perazzo, F.3
-
54
-
-
0026628657
-
Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers
-
Brion N, Kollenbach K, Marion MH, et al. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992; 15: 229-35
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 229-235
-
-
Brion, N.1
Kollenbach, K.2
Marion, M.H.3
-
55
-
-
0027494763
-
Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease
-
Mizuta E, Kuno S. Effect of D-penicillamine on pharmacokinetics of levodopa in Parkinson's disease Clin Neuropharmacol 1943; 16: 448-50
-
(1943)
Clin Neuropharmacol
, vol.16
, pp. 448-450
-
-
Mizuta, E.1
Kuno, S.2
-
57
-
-
0015983689
-
Levodopa-propranolol therapy in parkinsonian tremor
-
Kissel P, Tridon P, Andre JM. Levodopa-propranolol therapy in parkinsonian tremor [letter]. Lancet 1974; 1: 403-4
-
(1974)
Lancet
, vol.1
, pp. 403-404
-
-
Kissel, P.1
Tridon, P.2
Andre, J.M.3
-
58
-
-
0002859737
-
Adverse effects of levodopa
-
Olanow CW, Lieberman AN, editors. Park Ridge (NJ): Parthenon
-
Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The scientific basis for the treatment of Parkinson's disease. Park Ridge (NJ): Parthenon, 1992: 89-112
-
(1992)
The Scientific Basis for the Treatment of Parkinson's Disease
, pp. 89-112
-
-
Fahn, S.1
-
59
-
-
0029884740
-
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease
-
Carpentier AF, Bonnet AM, Vidailhet M, et al. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996; 46: 1548-51
-
(1996)
Neurology
, vol.46
, pp. 1548-1551
-
-
Carpentier, A.F.1
Bonnet, A.M.2
Vidailhet, M.3
-
60
-
-
0016430740
-
Diphenylhydantoin blocking of levodopa effects
-
Mendez JS, Cotzias GC, Mena I, et al. Diphenylhydantoin blocking of levodopa effects. Arch Neurol 1975; 32: 44-6
-
(1975)
Arch Neurol
, vol.32
, pp. 44-46
-
-
Mendez, J.S.1
Cotzias, G.C.2
Mena, I.3
-
61
-
-
0027159879
-
Oral levodopa/carbidopa solution versus tablets in Parkinson's disease with severe fluctuations: A pilot study
-
Kurth MC, Tetrud JW, Irwin I, et al. Oral levodopa/carbidopa solution versus tablets in Parkinson's disease with severe fluctuations: a pilot study. Neurology 1993; 43: 1036-9
-
(1993)
Neurology
, vol.43
, pp. 1036-1039
-
-
Kurth, M.C.1
Tetrud, J.W.2
Irwin, I.3
-
62
-
-
0027518164
-
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations
-
Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993; 43: 1698-703
-
(1993)
Neurology
, vol.43
, pp. 1698-1703
-
-
Kurth, M.C.1
Tetrud, J.W.2
Tanner, C.M.3
-
63
-
-
0029732865
-
Liquid levodopa/ carbidopa produces significant improvement in motor function without dyskinesia exacerbation
-
Pappert EJ, Goetz GC, Niederman F, et al. Liquid levodopa/ carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996; 47: 1493-5
-
(1996)
Neurology
, vol.47
, pp. 1493-1495
-
-
Pappert, E.J.1
Goetz, G.C.2
Niederman, F.3
-
64
-
-
0027324013
-
Suppression of dyskinesias in advanced Parkinson's disease: Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms
-
Bennett Jr JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-5
-
(1993)
Neurology
, vol.43
, pp. 1551-1555
-
-
Bennett Jr., J.P.1
Landow, E.R.2
Schuh, L.A.3
-
65
-
-
0016414699
-
The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl
-
Birkmayer W, Riederer P, Youdim MBH, et al. The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303-26
-
(1975)
J Neural Transm
, vol.36
, pp. 303-326
-
-
Birkmayer, W.1
Riederer, P.2
Youdim, M.B.H.3
-
66
-
-
0024456653
-
Effect of deprenyl on the progression of disability in early Parkinson's disease
-
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
-
(1989)
N Engl J Med
, vol.321
, pp. 1364-1371
-
-
-
67
-
-
0028835283
-
The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers
-
Roberts J, Waller DG, O'Shea N, et al. The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Br J Clin Pharmacol 1995; 40: 404-6
-
(1995)
Br J Clin Pharmacol
, vol.40
, pp. 404-406
-
-
Roberts, J.1
Waller, D.G.2
O'Shea, N.3
-
68
-
-
0026469784
-
The antiparkinsonian effect of deprenyl derives lrom transient improvement that is likely to be symptomatic
-
Schulzer M, Mak E, Calne DB. The antiparkinsonian effect of deprenyl derives lrom transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32: 795-8
-
(1992)
Ann Neurol
, vol.32
, pp. 795-798
-
-
Schulzer, M.1
Mak, E.2
Calne, D.B.3
-
69
-
-
0019972555
-
Possible development of serotonin syndrome in man
-
Insel TR, Roy BF, Cohen RM. Possible development of serotonin syndrome in man. Am J Psychiatry 1982; 139: 954-5
-
(1982)
Am J Psychiatry
, vol.139
, pp. 954-955
-
-
Insel, T.R.1
Roy, B.F.2
Cohen, R.M.3
-
73
-
-
0027500494
-
Pseudopheochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline
-
Monastruc JL, Chamontin B, Senard JM, et al. Pseudopheochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555
-
(1993)
Lancet
, vol.341
, pp. 555
-
-
Monastruc, J.L.1
Chamontin, B.2
Senard, J.M.3
-
74
-
-
0027980832
-
Fluoxetine and selegiline: Lack of significant interaction
-
Waters CH. Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 1994; 21: 259-61
-
(1994)
Can J Neurol Sci
, vol.21
, pp. 259-261
-
-
Waters, C.H.1
-
76
-
-
0026074757
-
Severe adverse interaction between pethidine and selegiline
-
Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246
-
(1991)
Lancet
, vol.337
, pp. 246
-
-
Zornberg, G.L.1
Bodkin, J.A.2
Cohen, B.M.3
-
77
-
-
0023408711
-
Unusual drug interactions between monamine oxidase inhibitors and tricyclic antidepressants
-
Richards GA, Fritz VU, Pincus P, et al. Unusual drug interactions between monamine oxidase inhibitors and tricyclic antidepressants. J Neurol Neurosurg Psychiatry 1987; 50: 1240-1
-
(1987)
J Neurol Neurosurg Psychiatry
, vol.50
, pp. 1240-1241
-
-
Richards, G.A.1
Fritz, V.U.2
Pincus, P.3
-
78
-
-
0023189808
-
Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction
-
Tackley RM, Tregakis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anesthesia 1987; 42: 760-3
-
(1987)
Anesthesia
, vol.42
, pp. 760-763
-
-
Tackley, R.M.1
Tregakis, B.2
-
79
-
-
0027935135
-
General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase
-
Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen Pharmacol 1994; 25: 813-24
-
(1994)
Gen Pharmacol
, vol.25
, pp. 813-824
-
-
Kaakkola, S.1
Gordin, A.2
Mannisto, P.T.3
-
80
-
-
0027514196
-
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
-
Keranen T, Gordin A, Harjla V-P, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145-56
-
(1993)
Clin Neuropharmacol
, vol.16
, pp. 145-156
-
-
Keranen, T.1
Gordin, A.2
Harjla, V.-P.3
-
81
-
-
0027770982
-
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
-
Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994; 44: 2685-8
-
(1994)
Neurology
, vol.44
, pp. 2685-2688
-
-
Roberts, J.W.1
Cora-Locatelli, G.2
Bravi, D.3
-
82
-
-
0025803672
-
Central action of benserazide after COMT inhibition demonstrated in vivo by PET
-
Tedroff J, Hartvig P, Bjurling P, et al. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm 1991; 85: 11-7
-
(1991)
J Neural Transm
, vol.85
, pp. 11-17
-
-
Tedroff, J.1
Hartvig, P.2
Bjurling, P.3
-
83
-
-
0016829492
-
Catechol-O-methyltransferase: Pharmacological aspects and physiological role
-
Guldberg HC, Marsden CD. Catechol-O-methyltransferase: pharmacological aspects and physiological role [letter]. Pharmacol Rev 1975; 27: 135-206
-
(1975)
Pharmacol Rev
, vol.27
, pp. 135-206
-
-
Guldberg, H.C.1
Marsden, C.D.2
-
84
-
-
0027343947
-
Treatment of drug-induced psychosis in Parkinson's disease with clozapine
-
Narbayashi H, Nagatsu T, Yangisawa N, et al., editors. New York (NY): Raven Press
-
Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. In: Narbayashi H, Nagatsu T, Yangisawa N, et al., editors. Advances in neurology. New York (NY): Raven Press, 1993: 703-6
-
(1993)
Advances in Neurology
, pp. 703-706
-
-
Greene, P.1
Cote, L.2
Fahn, S.3
-
85
-
-
0030819935
-
The emerging role of clozapine in the treatment of movement disorders
-
Factor SA, Friedman JM. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483-96
-
(1997)
Mov Disord
, vol.12
, pp. 483-496
-
-
Factor, S.A.1
Friedman, J.M.2
-
87
-
-
0024268376
-
Neuroleptic malignant syndrome after clozapine plus carbamazepine
-
Miller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; II: 1500
-
(1988)
Lancet
, vol.2
, pp. 1500
-
-
Miller, T.1
Becker, T.2
Fritze, J.3
-
88
-
-
0026078295
-
Effect of phenytoin on plasma clozapine concentrations in two patients
-
Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991; 52: 223-5
-
(1991)
J Clin Psychiatry
, vol.52
, pp. 223-225
-
-
Miller, D.D.1
-
90
-
-
0026014569
-
Possible interactions between clozapine and lorazepam
-
Cobb CD, Anderson CB, Seidel DR. Possible interactions between clozapine and lorazepam. Am J Psychiatry 1991; 148: 1606-7
-
(1991)
Am J Psychiatry
, vol.148
, pp. 1606-1607
-
-
Cobb, C.D.1
Anderson, C.B.2
Seidel, D.R.3
-
92
-
-
0024872485
-
Myoclonus during treatment with clozapine and lithium: The role of serotonin
-
Lemus CZ, Liberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11: 127-30
-
(1989)
Hillside J Clin Psychiatry
, vol.11
, pp. 127-130
-
-
Lemus, C.Z.1
Liberman, J.A.2
Johns, C.A.3
-
93
-
-
0022458560
-
Apparent neuroleptic malignant syndrome with clozapine and lithium
-
Pope HG, Cole JO, Choras PT, et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 1986; 174: 493-5
-
(1986)
J Nerv Ment Dis
, vol.174
, pp. 493-495
-
-
Pope, H.G.1
Cole, J.O.2
Choras, P.T.3
-
94
-
-
0029845563
-
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
-
Wolters ECH, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-7
-
(1996)
Neurology
, vol.47
, pp. 1085-1087
-
-
Wolters, E.C.H.1
Jansen, E.N.H.2
Tuynman-Qua, H.G.3
-
95
-
-
0028144914
-
Risperidone in Parkinson's disease
-
Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994; 344: 681
-
(1994)
Lancet
, vol.344
, pp. 681
-
-
Ford, B.1
Lynch, T.2
Greene, P.3
-
96
-
-
0029610790
-
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
-
Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
-
(1995)
J Clin Psychiatry
, vol.56
, pp. 556-559
-
-
Rich, S.S.1
Friedman, J.H.2
Ott, B.R.3
-
98
-
-
0023920165
-
Neuroleptic-induced Parkinson's syndrome: Clinical features and results with levodopa
-
Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850-4
-
(1988)
J Neurol Neurosurg Psychiatry
, vol.51
, pp. 850-854
-
-
Hardie, R.J.1
Lees, A.J.2
-
100
-
-
0027213299
-
Unilateral pallidal lesions after acute disulfiram intoxication: A clinical and magnetic resonance study
-
de Mari M, De Blasi R, Lamberti P. Unilateral pallidal lesions after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord 1993; 8: 247-9
-
(1993)
Mov Disord
, vol.8
, pp. 247-249
-
-
De Mari, M.1
De Blasi, R.2
Lamberti, P.3
-
101
-
-
0028217518
-
Chronic lithium neurotoxicity presenting as Parkinson's disease: A cross-sectional study of patients with 15 years or more on lithium
-
Lecamwasam D, Syneck B, Moyles K. Chronic lithium neurotoxicity presenting as Parkinson's disease: a cross-sectional study of patients with 15 years or more on lithium. Int Clin Psychopharmacology 1994; 9: 127-9
-
(1994)
Int Clin Psychopharmacology
, vol.9
, pp. 127-129
-
-
Lecamwasam, D.1
Syneck, B.2
Moyles, K.3
-
102
-
-
0026593291
-
Manganese intoxication during total parenteral nutrition
-
Ejima A, Imamura T, Nakamura S. Manganese intoxication during total parenteral nutrition [letter]. Lancet 1992; 339: 426
-
(1992)
Lancet
, vol.339
, pp. 426
-
-
Ejima, A.1
Imamura, T.2
Nakamura, S.3
-
104
-
-
0021360811
-
Parkinsonian side effects induced by a monoamine oxidase inhibitor
-
Teusink JP, Alexopoulos GS, Shamoian CA. Parkinsonian side effects induced by a monoamine oxidase inhibitor. Am J Psychiatry 1984; 141: 118-9
-
(1984)
Am J Psychiatry
, vol.141
, pp. 118-119
-
-
Teusink, J.P.1
Alexopoulos, G.S.2
Shamoian, C.A.3
-
105
-
-
0026729474
-
Exacerbation of Parkinsonism by tacrine
-
Ott BR, Lannon MC. Exacerbation of Parkinsonism by tacrine. Clin Neuropharmacol 1992; 15: 322-5
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 322-325
-
-
Ott, B.R.1
Lannon, M.C.2
-
107
-
-
0019944931
-
Metoclopramide-induced parkinsonism
-
Indo T, Ando K. Metoclopramide-induced parkinsonism. Arch Neurol 1982; 39: 494-6
-
(1982)
Arch Neurol
, vol.39
, pp. 494-496
-
-
Indo, T.1
Ando, K.2
-
108
-
-
0026500949
-
Parkinsonian syndrome after long-term treatment with clebopride
-
Montagna P, Gabellini AS, Montari I, et al. Parkinsonian syndrome after long-term treatment with clebopride. Mov Disord 1992; 7: 89-90
-
(1992)
Mov Disord
, vol.7
, pp. 89-90
-
-
Montagna, P.1
Gabellini, A.S.2
Montari, I.3
-
109
-
-
0029076276
-
Effects of calcium antagonists on the dopamine system
-
Mena AM, de Yebenes MJG, Taberno C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995; 18: 410-26
-
(1995)
Clin Neuropharmacol
, vol.18
, pp. 410-426
-
-
Mena, A.M.1
De Mjg, Y.2
Taberno, C.3
-
110
-
-
0023228052
-
Flunarizine and cinnarizine-induced extrapyramidal reactions
-
Micheli F, Fernandez Pardel M, Gatto M, et al. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 37: 881-4
-
(1987)
Neurology
, vol.37
, pp. 881-884
-
-
Micheli, F.1
Fernandez Pardel, M.2
Gatto, M.3
-
112
-
-
0024322957
-
Diltiazem-induced parkinsonism
-
Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95-6
-
(1989)
Am J Med
, vol.87
, pp. 95-96
-
-
Dick, R.S.1
Barold, S.S.2
-
113
-
-
0028966583
-
Amiodarone-induced parkinsonism: A case report and pathogenetic discussion
-
Dotti M, Frederico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10: 233-4
-
(1995)
Mov Disord
, vol.10
, pp. 233-234
-
-
Dotti, M.1
Frederico, A.2
-
114
-
-
0022624892
-
Buspirone: Review of its pharmacology and current perspective on its method of action
-
Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspective on its method of action. Am J Med 1986 Suppl. 3B: 1-9
-
(1986)
Am J Med
, Issue.SUPPL. 3B
, pp. 1-9
-
-
Eison, A.S.1
Temple, D.L.2
-
115
-
-
0027242157
-
Persistent movement disorders induced by buspirone
-
LeWitt PA, Walters A, Hening W, et al. Persistent movement disorders induced by buspirone. Mov Disord 1993; 8: 331-4
-
(1993)
Mov Disord
, vol.8
, pp. 331-334
-
-
Lewitt, P.A.1
Walters, A.2
Hening, W.3
-
116
-
-
0027508276
-
Parkinsonism in childhood after sodium valproate administration
-
Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonism in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451-5
-
(1993)
Clin Neuropharmacol
, vol.16
, pp. 451-455
-
-
Alvarez-Gomez, M.J.1
Vaamonde, J.2
Narbona, J.3
-
118
-
-
0020532969
-
Galactorrhea as a side-effect of domperidone
-
Cann PA, Read NW, Holdsworth CD. Galactorrhea as a side-effect of domperidone. BMJ 1983; 286: 1395-6
-
(1983)
BMJ
, vol.286
, pp. 1395-1396
-
-
Cann, P.A.1
Read, N.W.2
Holdsworth, C.D.3
-
119
-
-
0025733720
-
Psychotic complications of long term levodopa treatment of Parkinson's disease
-
Friedman A, Sienkiewicz J. Psychotic complications of long term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991; 84: 111-3
-
(1991)
Acta Neurol Scand
, vol.84
, pp. 111-113
-
-
Friedman, A.1
Sienkiewicz, J.2
-
120
-
-
0025766667
-
The management of the levodopa psychoses
-
Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991; 12: 283-95
-
(1991)
Clin Neuropharmacol
, vol.12
, pp. 283-295
-
-
Friedman, J.H.1
-
121
-
-
0029161630
-
Psychosis in advanced Parkinso's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist
-
Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinso's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 47: 1305-8
-
(1995)
Neurology
, vol.47
, pp. 1305-1308
-
-
Zoldan, J.1
Friedberg, G.2
Livneh, M.3
-
122
-
-
0023197778
-
Preoperative management of the surgical patient with neurologic disease
-
Merli GJ, Bell RD. Preoperative management of the surgical patient with neurologic disease. Med Clin North Am 1987; 71 (3): 511
-
(1987)
Med Clin North Am
, vol.71
, Issue.3
, pp. 511
-
-
Merli, G.J.1
Bell, R.D.2
-
124
-
-
0024353822
-
Acute postoperative confusion and hallucinations in PD
-
Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and hallucinations in PD. Ann Intern Med 1989; 111: 218-22
-
(1989)
Ann Intern Med
, vol.111
, pp. 218-222
-
-
Golden, W.E.1
Lavender, R.C.2
Metzer, W.S.3
-
125
-
-
7144246131
-
Neurologic syndromes and their disorders with their anesthetic implications
-
Albin MS, editor. New York (NY): McGraw Hill
-
Solomon D, Solomon D, Albin M. Neurologic syndromes and their disorders with their anesthetic implications. In: Albin MS, editor. Textbook of neuroanesthesia. New York (NY): McGraw Hill, 1997: 409-11
-
(1997)
Textbook of Neuroanesthesia
, pp. 409-411
-
-
Solomon, D.1
Solomon, D.2
Albin, M.3
-
126
-
-
0025759946
-
Acute dystonia after alfentanil in untreated Parkinson's disease
-
Mets B. Acute dystonia after alfentanil in untreated Parkinson's disease. Anesth Analg 1991; 72: 557-8
-
(1991)
Anesth Analg
, vol.72
, pp. 557-558
-
-
Mets, B.1
-
127
-
-
0025065137
-
Treatment of hypertensive crisis
-
Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med 1990; 323: 1177-83
-
(1990)
N Engl J Med
, vol.323
, pp. 1177-1183
-
-
Calhoun, D.A.1
Oparil, S.2
-
129
-
-
0029103428
-
The serotonin syndrome: Implicated drugs, pathophysiology and management
-
Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995; 13: 94-104
-
(1995)
Drug Saf
, vol.13
, pp. 94-104
-
-
Sporer, K.A.1
-
130
-
-
0028143258
-
Fluoxetine and the serotonin syndrome
-
Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983-5
-
(1994)
Ann Emerg Med
, vol.24
, pp. 983-985
-
-
Ruiz, F.1
-
131
-
-
0027965174
-
Treatment of the serotonin syndrome with cyproheptadine
-
Lappin RI, Auchinloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331: 1021-2
-
(1994)
N Engl J Med
, vol.331
, pp. 1021-1022
-
-
Lappin, R.I.1
Auchinloss, E.L.2
|